RTGN: RetinalGenix Technologies Inc. Stock

SIC 3841 – Surgical and Medical Instruments and Apparatus

Valuation
Market Cap ($M) 64.83
Enterprise Value ($M) 65.34
Book Value ($M) -1.46
Book Value / Share -0.08
Price / Book -44.32
NCAV ($M) -1.47
NCAV / Share -0.08
Price / NCAV -44.06

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -85.53
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.00
Current Ratio 0.00

Balance Sheet (mrq) ($M)
Current Assets 0.01
Assets 0.01
Liabilities 1.48
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -4.32
Net Income -4.32
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -0.74
Cash from Investing 0.00
Cash from Financing 0.75

(click for more detail)
Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-31 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐TRANSITION REPORT PURSUANT TO SECTIO
2024-11-18 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT
2024-08-19 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURS
2024-05-20 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PUR

(click for more detail)

Similar Companies
RDGL – Vivos Inc. REMI – Remedent, Inc.
RGIN – Regenicin, Inc. RYLPF – Koninklijke Philips N.V.
SAUHF – Straumann Holding AG


Financial data and stock pages provided by
Fintel.io